Overcoming Comparability Issues in
Regenerative Medicines Manufacturing
The Latest on Cell and Gene Therapy Regulation


Wednesday, July 22, 2020 • 1:30 p.m. - 3:00 p.m. EDT

Comparability studies may be the most significant challenge in the development and commercialization of regenerative medicine products⁠ — and the difficulties only become more pressing as development progresses. In the course of gaining final approval, a product’s materials and methods will likely evolve. These evolutions may improve the therapy, but they risk its critical quality attributes, or CQAs. Comparability studies mitigate those risks and allow manufacturers to retain those CQAs. A successful study will match the level of changes, with stricter comparability needed as greater adjustments accumulate.

Do you thoroughly understand comparability requirements and how to meet them?

In this FDAnews webinar, Scott R. Burger will discuss how to best navigate the FDA’s stipulations around these studies. He will share best practices around determining the necessary level of your comparability study, planning and preparing for your analysis, and avoiding common mistakes in a package for the FDA.

Key Webinar Takeaways:

  • FDA Requirements for Comparability Studies
    1. Assembling the best comparability package

  • Risk Analysis and Mitigation
    1. Best practices around comparability study risks
    2. Determining the necessary rigor of a comparability study

  • Designing an Effective Comparability Protocol
    1. Using the right analytical tools, samples, and statistical analyses
    2.   In vitro versus in vivo comparability studies
    3.   Understand common mistakes and how to avoid them

  • Statistical Comparability Approaches

Managing comparability studies to achieve approval for regenerative medicine products is a complicated but imperative process. Ensure your products retain their CQAs and meet all FDA requirements. Join us by registering today.

Who Will Benefit

  • Pharmaceutical and biopharma staff developing cell and gene therapy products
  • Product and service providers supporting cell and gene therapies
  • Cell and gene therapy CMOs and CDMOs
  • Quality and regulatory affairs staff
  • Manufacturing process development and analytics staff
  • Research and development staff
  • Senior management at companies developing cell and gene therapies

Webinar plus Recording & Transcript Bundle
Learn more

$487

add to cart

Webinar only
Learn more

$287

add to cart

24/7 Encore plus Recording & Transcript Bundle
Learn more

$487

add to cart

24/7 Encore Presentation
Learn more

$287

add to cart

Webinar Recording & Transcript Bundle
Learn more

$287

add to cart

 

Meet Your Presenter

Scott R. Burger, MD

Principal
Advanced Cell and Gene Therapy

Scott R. Burger, MD, is the principal of Advanced Cell and Gene Therapy, a consulting firm specializing in the development, manufacturing, and regulatory affairs of cell and gene therapy products. Mr. Burger has more than 25 years of experience developing these products and has consulted for over 140 companies in North America, Europe, Asia, and Australia. He has directed and consulted on process development, manufacturing, and CMC regulatory aspects of a wide range of cell and gene therapy products, including CAR T-cell, NK, and DC immunotherapies, gene-edited cell therapy products, and stem cell- and somatic cell-based regenerative medicine products.

MII logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 | Fax 703.538.7676 | Toll free 888.838.5578 | Email customerservice@fdanews.com

© 2020 FDAnews